Century Therapeutics, LLC

37 articles with Century Therapeutics, LLC

• Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

  5/16/2022

  Century Therapeutics, Inc. reported financial results and business highlights for the first quarter ended March 31, 2022.

• Century Therapeutics to Present at Upcoming Investor Conferences in May 2022

  5/3/2022

  Century Therapeutics announced that members of the management team will participate in the following investor conferences in May.

• Century Therapeutics to Present at the ASGCT 25th Annual Meeting

  5/2/2022

  Century Therapeutics announced that preclinical data on MAD7, a novel CRISPR nuclease used to enable the genetic engineering of iPSC-derived NK and T cell product candidates, will be presented in a poster at the American Society of Gene and Cell Therapy 25th Annual Meeting, on May 16-19, 2022 in Washington, D.C.

• Century Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

  4/6/2022

  Century Therapeutics announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 10:15 AM ET and participate in a panel titled “Company Perspectives: Companies Discussing Key Features and Differentiators in the NK Cellular Therapeutics Space” on April 14, 2022, at 11:00 AM ET.

• Century Therapeutics to Present at the H.C. Wainwright Gene Therapy and Gene Editing Conference

  3/23/2022

  Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright Gene Therapy and Gene Editing Conference, being held virtually on March 30, 2022.

• Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates

  3/17/2022

  “Throughout 2021, we continued to make steady progress in developing our comprehensive, next-generation iPSC-based cell therapy platform, executed on our powerful discovery engine, and we believe we are positioned to transition to a clinical stage company in 2022.

• Century Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

  2/9/2022

  Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, announced that members of the senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 1:40 PM ET.

• Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies

  1/10/2022

  Century Therapeutics and Bristol Myers Squibb announced a research collaboration and license agreement to develop and commercialize up to four induced pluripotent stem cell derived, engineered natural killer cell and / or T cell programs for hematologic malignancies and solid tumors.

• 

  BMS and Century Therapeutics Will Combine Cell Therapy Forces Against Cancer

  1/10/2022

  BMS and Century Therapeutics agreed to collaborate on the research, development, and commercialization of up to four T cell programs for hematologic malignancies and solid tumors.

• Century Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/4/2022

  Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 1:30 PM ET.

• Century Therapeutics Added to the NASDAQ Biotechnology Index

  12/17/2021

  Century Therapeutics today announced it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective as of market open on Monday, December 20, 2021.

• Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Provides Pipeline Updates

  12/16/2021

  Century Therapeutics today announced updated preclinical data from the Company’s CNTY-101 program and CAR-iT platform.

• Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

  11/10/2021

  Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates. Research and development update to be held on Thursday, December 16, 8:00-9:30 AM EST

• Century Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Host Virtual Research & Development Update

  11/4/2021

  Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, announced that preclinical data from the Company’s CNTY-101 program and CAR-iT platform will be presented in two posters at the 63rd American Society of Hematology Annual Meeting & Exposition, on December 11-14, 2021 in Atlanta, Georgia and virtually.

• Century Therapeutics and Outpace Bio Enter Research Collaboration in CAR Engineering

  10/7/2021

  Collaboration enables Century to explore Outpace’s protein solutions for cell therapy to enhance functionality of iPSC platform Initial program to focus on hematological malignancies with option to expand to additional candidates

• Century Therapeutics Announces Its Addition to the Russell 2000® Index

  9/17/2021

  Century Therapeutics announced that it will be added to the small-cap Russell 2000® Index as a part of the 3Q21 Russell Indexes IPO additions, effective at US market open on September 20, 2021, according to the preliminary list of IPO additions to the Russell indexes.

• Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates

  8/12/2021

  Century Therapeutics, (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the second quarter ended June 30, 2021.

• Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  6/22/2021

  Century Therapeutics  today announced the closing of its initial public offering of 12,132,500 shares of its common stock at a public offering price of $20.00 per share, which includes the full exercise by the underwriters of their option to purchase 1,582,500 additional shares of common stock.

• Century Therapeutics Announces Pricing of Initial Public Offering

  6/17/2021

  Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the pricing of its initial public offering of 10,550,000 shares of its common stock at a public offering price of $20.00 per share

• Century Therapeutics Adds Respected Biotech Executives to Board of Directors

  6/1/2021

  Century Therapeutics , a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Alessandro Riva , M.D., and Kimberly Blackwell, M.D., as new Independent Directors.